Characterisation of an inclusion complex between cladribine and 2-hydroxypropyl-β-cyclodextrin

Journal of Pharmaceutical Sciences

Volumn 97, Issue 9, 2008, Pages 3897-3906

  Van Axel Castelli, Valeria ^a   Trivieri, Giovanni ^a   Zucchelli, Ilaria ^a   Brambilla, Luigi ^b   Barbuzzi, Tony ^a   Castiglioni, Chiara ^b   Paci, Maurizio ^c   Zerbi, Giuseppe ^b   Zanol, Margherita ^a  

^a Merck Serono SpA   (Italy)

^b POLITECNICO DI MILANO   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cladribine; Cyclodextrins; FT IR; Inclusion compounds; NMR spectroscopy; Oral drug delivery; Thermal analysis

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; CLADRIBINE;

ARTICLE; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STORAGE; DRUG STRUCTURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL CHEMISTRY;

EID: 53549088887     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21283     Document Type: Article

References (37)

1. Gottberg K, Gardulf A, Fredrikson S. 2000. Inter-feron-beta treatment for patients with multiple sclerosis: The patients' perceptions of the side-effects. Mult Scier 6:349-354.
2. Albertioni F, Juliusson G, Liliemark J. 1993. On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole. Eur J Clin Pharmacol 44:579-582.
3. Zhong M, Nowak I, Robins MJ. 2006. Regiospecific and highly stereoselective coupling of 6-(substituted-imidazol-1-yl) purines with 2-deoxy-3,5-di-0-(p-toluoyl)-alpha-D-erythro-pentofuranosyl chloride. Sodium-salt glycosylation in binary solvent mixtures: Improved synthesis of cladribine. J Org Chem 71:7773-7779.
4. Robak T. 2006. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat Rev 32:365-376.
5. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. 1996. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci USA 93:1716-1720.
6. Rice GP, Filippi M, Comi G. 2000. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54:1145-1155.
7. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. 1999. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 111:35-44.
8. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. 1994. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344:9-13.
9. Uekama K, Hirayama F, Irie T. 1998. Cyclodextrin drug carrier systems. Chem Rev 98:2045-2076.
10. Loftsson T, Brewster ME. 1996. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci 85:1017-1025.
11. Szejtli J. 1998. Introduction and general overview of cyclodextrin chemistry. Chem Rev 98:1743-1754.
12. Mura P, Bettinetti GP, Manderioli A, Faucci MT, Bramanti G, Sorrenti M. 1998. Interactions of ketoprofen and ibuprofen with beta-cyclodextrins in solution and in solid state. Int J Pharm 166:189-203.
13. Redenti E, Zanol M, Ventura P, Fronza G, Comotti A, Taddei P, Bertoluzza A. 1999. Raman and solid state 13C-NMR investigation of the structure of the 1:1 amorphous piroxicam: Beta-cyclodextrin inclusion compound. Biospectroscopy 5:243-251.
14. Rao VM, Haslam JL, Stella VJ. 2001. Controlled and complete release of a model poorly water-soluble drug, prednisolone, from hydroxypropyl methyl-cellulose matrix tablets using (SBE)(7m)-beta-cyclodextrin as a solubilizing agent. J Pharm Sci 90:807-816.
15. Taddei P, Torreggiani A, Simoni R. 2001. Influence of environment on piroxicam polymorphism: Vibrational spectroscopic study. Biopolymers 62:68-78.
16. Baboota S, Agarwal SP. 2005. Preparation and characterization of meloxicam hydroxypropyl-b-cyclodextrin inclusion complex. J Incl Phenom Macrocycl Chem 51:219-224.
17. Shen YL, Yang SH, Wu LM, Ma XY. 2005. Study on structure and characterization of inclusion complex of gossypol/beta cyclodextrin. Spectrochim Acta A Mol Biomol Spectrosc 61: 1025-1028.
18. Sinha VR, Anitha R, Ghosh S, Nanda A, Kumria R. 2005. Complexation of celecoxib with beta-cyclodextrin: Characterization of the interaction in solution and in solid state. J Pharm Sci 94:676-687.
19. Yuexian F, Junfen L, Chuan D. 2005. Preparation and study on the inclusion complexes of two tanshinone compounds with beta-cyclodextrin. Spectrochim Acta A Mol Biomol Spectrosc 61: 135-140.
20. Choi SH, Kim SY, Ryoo JJ, Park JY, Lee KP. 2001. FT-Raman and FT-IR spectra of the non-steroidal anti-inflammatory drug ketoprofen included in cyclodextrins. Anal Sci 17:i1785-i1788.
21. Uekama K, Horikawa T, Yamanaka M, Hirayama F. 1994. Peracylated beta-cyclodextrins as novel sustained-release carriers for a water-soluble drug, molsidomine. J Pharm Pharmacol 46:714-717.
22. Uekama K, Hirayama F, Arima H. 2006. Recent aspect of cyclodextrin-based drug delivery system. J Incl Phenom Macrocycl Chem 56:3-8.
23. Blanchemain N, Haulon S, Boschin F, Marcon-Bachari E, Traisnel M, Morcellet M, Hildebrand HF, Martel B. 2007. Vascular prostheses with controlled release of antibiotics Part 1: Surface modification with cyclodextrins of PET prostheses. Biomol Eng 24:149-153.
24. Higashi T, Hirayama F, Arima H, Uekama K. 2007. Polypseudorotaxanes of pegylated insulin with cyclodextrins: Application to sustained release system. Bioorg Med Chem Lett 17:1871-1874.
25. Nolan D, Darcy R, Ravoo BJ. 2003. Preparation of vesicles and nanoparticles of amphiphilic cyclodextrins containing labile disulfide bonds. Langmuir 19:4469-4472.
26. Bodor NS, inventor. 2004. Cladribine formulations for improved oral and transmucosal delivery. Patent Cooperation Treaty international publication number: WO/2004/087100.
27. Giordano F, Novak C, Moyano JR. 2001. Thermal analysis of cyclodextrins and their inclusion compounds. Thermochimica Acta 380:123-151.
28. Hwang TL, Shaka AJ. 1995. Water suppression that works: Excitation sculpting using arbitrary waveforms and pulse field gradients. J Magn Reson A 112:275-279.
29. Ababou A, Ladbury JE. 2006. Survey of the year 2004: Literature on applications of isothermal titration calorimetry. J Mol Recognit 19:79-89.
30. Cheng Y, Hercules DM. 2001. Measurement of chiral complexes of cyclodextrins and amino acids by electrospray ionization time-of-flight mass spectrometry. J Mass Spectrom 36:834-836.
31. Lamcharfi E, Chuilon S, Kerbal A, Kunesch G, Libot F, Virelizier H. 1996. Electrospray ionization mass spectrometry in supramolecular chemistry: Characterization of noncovalent cyclodextrin complexes. J Mass Spectrom 31:982-986.
32. Bakhtiar R, Hop CE. 1997. A study of the complexation between dimethyl-beta-cyclodextrin and steroid hormones using electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 11: 1478-1481.
33. Ramanathan R, Prokai L. 1995. Electrospray ionization mass spectrometric study of encapsulation of amino acids by cyclodextrins. J Am Soc Mass Spectrom 12:866-871.
34. Ahn S, Ramirez J, Grigorean G, Lebrilla CB. 2001. Chiral recognition in gas-phase cyclodextrin: Amino acid complexes - Is the three point interaction still valid in the gas phase? J Am Soc Mass Spectrom 12:278-287.
35. Meier MM, Bordignon Luiz MT, Farmer PJ, Szpo-ganicz B. 2001. The influence of beta- and gamma-cyclodextrin cavity size on the association constant with decanoate and octanoate anions. J Incl Phenom Macrocycl Chem 40:291-295.
36. Tongiani S, Velde DV, Ozeki T, Stella VJ. 2005. Sulfoalkyl ether-alkyl ether cyclodextrin derivatives, their synthesis, NMR characterization, and binding of 6alpha-methylprednisolone. J Pharm Sci 94:2380-2392.
37. Berger S, Braun S. 2004. 200 and more NMR experiments, 4th edition. Weinheim: Wiley-VCH Verlag.